Exane BNP Paribas Upgrades Omega Healthcare Invts to Neutral, Announces $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Exane BNP Paribas analyst Nate Crossett upgrades Omega Healthcare Invts (OHI) from Underperform to Neutral and sets a $30 price target.
February 08, 2024 | 11:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Omega Healthcare Invts was upgraded by Exane BNP Paribas from Underperform to Neutral with a new price target of $30.
The upgrade from Underperform to Neutral by a notable analyst could lead to increased investor confidence in Omega Healthcare Invts, potentially driving up the stock price in the short term. The new price target of $30 suggests a positive outlook on the stock's value.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100